Axogen Financial Results
Axogen reported Q3 2026 revenue of $75.8 million, a 26.2% increase year-over-year, and raised its full-year revenue guidance to at least $290 million. The company also highlighted the completion of its BioCircuit Technologies acquisition and a successful $225 million equity raise during the period.
“We are delighted with our third-quarter and year-to-date revenue performance and the progress we continue to make across each of Axogen’s strategic plan priorities. Our strong growth across all markets, continues to validate our market development strategies and the strength of our commercial execution. We remain well positioned to achieve our 2026 revenue guidance and longer-term strategic objectives.”
Michael Dale, President and CEO of Axogen, Inc.